What is it about?
Tadalafil, a phosphodiesterase type 5 inhibitor, has a high potential for treating male lower urinary tract symptoms; however, there are few reports regarding which portion of the population is appropriate for treatment with tadalafil. This study showed that the baseline urine levels of miR-21-5p, an endothelium-associated miRNA, strongly correlates with response to tadalafil and have the potential to be a predictive biomarker of whether treatment with tadalafil is suitable.
Featured Image
Why is it important?
We confirmed that urine expression patterns of miRNAs associated with endothelial function possibly correlate with effectiveness of tadalafil treatment in mLUTS/BPH patients. Particularly, the baseline urine levels of miR-21-5p could be a promising biomarker predictive for its response.
Perspectives
All evidence from this study showed that urine levels of three endothelium-associated miRNAs (miR-21-5p, miR126-5p, miR-155-5p) have a potential for correlation with the treatment response to tadalafil in mLUTS/BPH patients. In particular, the baseline urine level of miR-21-5p exerted an excellent prediction for effectiveness of tadalafil in those patients. The next step is to determine whether urine levels of these miRNAs also associate with endothelial function values and vesical blood circulation in a large number of patients. Finally, the determination ofappropriatecut-off values of urine levels in endothelial miRNAs will lead to atailor-made medication of tadalafil for mLUTS/BPH patients.
Tomoaki Tanaka
Osaka City University Graduate School of Medicine
Read the Original
This page is a summary of: Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia, Future Science OA, July 2018, Future Science,
DOI: 10.4155/fsoa-2018-0012.
You can read the full text:
Contributors
The following have contributed to this page
